Add like
Add dislike
Add to saved papers

Synthesis and characterization of facial and meridional tris-cyclometalated iridium(III) complexes.

The synthesis, structures, electrochemistry, and photophysics of a series of facial (fac) and meridional (mer) tris-cyclometalated Ir(III) complexes are reported. The complexes have the general formula Ir(C'N)(3) [where C'N is a monoanionic cyclometalating ligand; 2-phenylpyridyl (ppy), 2-(p-tolyl)pyridyl (tpy), 2-(4,6-difluorophenyl)pyridyl (46dfppy), 1-phenylpyrazolyl (ppz), 1-(4,6-difluorophenyl)pyrazolyl (46dfppz), or 1-(4-trifluoromethylphenyl)pyrazolyl (tfmppz)]. Reaction of the dichloro-bridged dimers [(C'N(2)Ir(mu-Cl)(2)Ir(C'N)(2)] with 2 equiv of HC( wedge )N at 140-150 degrees C forms the corresponding meridional isomer, while higher reaction temperatures give predominantly the facial isomer. Both facial and meridional isomers can be obtained in good yield (>70%). The meridional isomer of Ir(tpy)(3) and facial and meridional isomers of Ir(ppz)(3) and Ir(tfmppz)(3) have been structurally characterized using X-ray crystallography. The facial isomers have near identical bond lengths (av Ir-C = 2.018 A, av Ir-N = 2.123 A) and angles. The three meridional isomers have the expected bond length alternations for the differing trans influences of phenyl and pyridyl/pyrazolyl ligands. Bonds that are trans to phenyl groups are longer (Ir-C av = 2.071 A, Ir-N av = 2.031 A) than when they are trans to heterocyclic groups. The Ir-C and Ir-N bonds with trans N and C, respectively, have bond lengths very similar to those observed for the corresponding facial isomers. DFT calculations of both the singlet (ground) and the triplet states of the compounds suggest that the HOMO levels are a mixture of Ir and ligand orbitals, while the LUMO is predominantly ligand-based. All of the complexes show reversible oxidation between 0.3 and 0.8 V, versus Fc/Fc(+). The meridional isomers are easier to oxidize by ca. 50-100 mV. The phenylpyridyl-based complexes have reduction potentials between -2.5 and -2.8 V, whereas the phenylpyrazolyl-based complexes exhibit no reduction up to the solvent limit of -3.0 V. All of the compounds have intense absorption bands in the UV region assigned into (1)(pi --> pi) transitions and weaker MLCT (metal-to-ligand charge transfer) transitions that extend to the visible region. The MLCT transitions of the pyrazolyl-based complexes are hypsochromically shifted relative to those of the pyridyl-based compounds. The phenylpyridyl-based Ir(III) tris-cyclometalates exhibit intense emission both at room temperature and at 77 K, whereas the phenylpyrazolyl-based derivatives emit strongly only at 77 K. The emission energies and lifetimes of the phenylpyridyl-based complexes (450-550 nm, 2-6 micros) and phenylpyrazolyl-based compounds (390-440 nm, 14-33 micros) are characteristic for a mixed ligand-centered/MLCT excited state. The meridional isomers for both pyridyl and pyrazolyl-based cyclometalates show markedly different spectroscopic properties than do the facial forms. Isolated samples of mer-Ir(C( wedge )N)(3) complexes can be thermally and photochemically converted to facial forms, indicating that the meridional isomers are kinetically favored products. The lower thermodynamic stabilities of the meridional isomers are likely related to structural features of these complexes; that is, the meridional configuration places strongly trans influencing phenyl groups opposite each other, whereas all three phenyl groups are opposite pyridyl or pyrazolyl groups in the facial complexes. The strong trans influence of the phenyl groups in the meridional isomers leads to the observation that they are easier to oxidize, exhibit broad, red-shifted emission, and have lower quantum efficiencies than their facial counterparts.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app